NANOBIOTIX Announces Presentation of new Data From Phase 1 I

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic...

Related Keywords

Tampa , Florida , United States , Texas , Baltimore , Maryland , France , Massachusetts , University Of Chicago , Illinois , University Of North Carolina , North Carolina , New York , Chicago , Arizona , Paris , France General , Chapel Hill , Cambridge , Cambridgeshire , United Kingdom , American , David Rolando , Jared Weiss , Septimiu Murgu , Brandon Owens , Paul Chang , Tanguy Seiwert , Aditya Joolori , Omari Vivar , Siddharth Sheth , Colette Shen , Laurent Wormser , George Yang , Trevor Hackman , Jimmy Caudell , Jiaxin Niu , Kedar Kirtane , Kevin Gardner , Jessica Frakes , Shetal Patel , Moffitt Cancer Center , University Of Texas Md Anderson Cancer Center , Twitter , Euronext , Banner Md Anderson Cancer Center , Given The Company , Linkedin , Nasdaq , Communications Department , University Of North Carolina School Medicine , Drug Administration , Investor Relations Department , Coordinating Investigator Colette Shen , American Society , Investigator Colette Shen , Laurent Levy , Sunday June , North Carolina School , Cancer Center , Hopkins Medicine , United States Food , Fast Track , Janssen Pharmaceutica , Euronext Paris , Nasdaq Global Select Market , New York City , Private Securities Litigation Reform Act , Annual Report ,